CriticalSelective serotonin reuptake inhibitors×First-generation antipsychotic, diphenylbutylpiperidine derivative
Updated · Methodology
Mechanism
The liver clears pimozide mainly through the enzymes CYP3A4 and CYP2D6, and to a lesser extent CYP1A2. The Spanish pimozide summary of product characteristics (SmPC) names fluoxetine among the antidepressants that may inhibit pimozide metabolism through CYP2D6 (pimozide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Fluoxetine is a potent CYP2D6 inhibitor (fluoxetine SmPC, AEMPS). With paroxetine, another strong CYP2D6 inhibitor, the pimozide area under the curve (AUC) rose by a mean of 151% and peak concentration by 62% (pimozide SmPC, AEMPS, and label, US Food and Drug Administration, FDA). The higher the pimozide level, the higher the risk of QT prolongation, and fluoxetine can prolong the QT interval itself (pimozide SmPC, AEMPS; fluoxetine FDA label). No study has tested pimozide with fluoxetine directly. The US fluoxetine label restricts the pair because of the potential for interaction and QT prolongation seen in studies of pimozide with other antidepressants (fluoxetine FDA label).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. With pimozide, QT prolongation, torsade de pointes, ventricular tachycardia and ventricular fibrillation, sometimes fatal, cardiac arrest and sudden death have been reported (pimozide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Rare case reports suggest that pimozide and fluoxetine together may slow the heart rate, causing bradycardia (pimozide label, US Food and Drug Administration, FDA). With neuroleptics, fluoxetine rarely causes serotonin syndrome or a state that resembles neuroleptic malignant syndrome. Signs include fever, muscle rigidity, muscle jerks, swings in pulse and blood pressure, and confusion and agitation that can progress to delirium and coma (fluoxetine SmPC, AEMPS).
Management
The combination is contraindicated. The US fluoxetine labels contraindicate pimozide by name (fluoxetine labels, US Food and Drug Administration, FDA). The Spanish pimozide summary of product characteristics (SmPC) contraindicates pimozide with CYP2D6 inhibitors and names fluoxetine among the drugs that may slow pimozide metabolism through this enzyme (pimozide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US pimozide label contraindicates pimozide with paroxetine and other strong CYP2D6 inhibitors (pimozide FDA label). The Spanish fluoxetine SmPC describes fluoxetine as a potent inhibitor of this enzyme (fluoxetine SmPC, AEMPS). Under the Spanish SmPC, pimozide is not used in depressive disorders, with other QT-prolonging drugs, with low potassium or magnesium, or with clinically significant bradycardia (pimozide SmPC, AEMPS). Fluoxetine and its active metabolite norfluoxetine stay in the body for 5–6 weeks after stopping. Take their long half-life into account when assessing interactions (fluoxetine SmPC, AEMPS). The documents do not give an exact interval before starting pimozide. Record an electrocardiogram (ECG) before starting pimozide and repeat it during treatment. If QT prolongation, T-wave changes, U waves or arrhythmias appear, lower the pimozide dose or stop it. Stop pimozide if the QT or corrected QT interval (QTc) exceeds 500 ms (pimozide SmPC, AEMPS). Correct low potassium before starting pimozide and keep it normal throughout treatment (pimozide FDA label). If fluoxetine and pimozide have nevertheless been taken together and signs of arrhythmia appear, stop fluoxetine and record an ECG (fluoxetine SmPC, AEMPS). In serotonin syndrome or a neuroleptic malignant syndrome-like state, stop fluoxetine and start supportive treatment (fluoxetine SmPC, AEMPS). In neuroleptic malignant syndrome, stop pimozide at once as well (pimozide SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Pimozide tablets, USP (ANI Pharmaceuticals) – prescribing information (2026)– FDA label, ANI Pharmaceuticals, DailyMed setid 4e954fc2-fdff-486c-beb6-2b8ace717081, version 3, 07/2026, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- FDA: Prozac (fluoxetine) prescribing information (2026)– FDA label, DailyMed setid c88f33ed-6dfb-4c5e-bc01-d8e36dd97299, version 59, revised 01/2026, section 7.7 Drugs Metabolized by CYP2D6
- AEMPS: Ficha técnica: Fluoxetina, Fluoxetina Cinfa 20 mg (nº registro 63499) (2026)– AEMPS, CIMA, nº registro 63499 (Fluoxetina Cinfa 20 mg cápsulas duras EFG), revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Orap (pimozida) (nº registro 49503), secciones 4.3 y 4.5 (2026)– AEMPS, CIMA, nº registro 49503, revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Orap (pimozida) (nº registro 49503), sección 4.3 (2026)– AEMPS, CIMA, nº registro 49503, revisión 10/2026, secciones 4.3, 4.4 y 4.5